Table 5.

Pair-wise comparison of various maintenance treatment groups for treatment outcomes in proliferative lupus nephritis. Mycophenolate sodium (MPS), when compared to the others [a group comprising cyclophosphamide and miscellaneous immunosuppressive agents excluding mycophenolate mofetil (MMF)] as a maintenance agent showed a significantly better complete and partial remission rates in proliferative lupus nephritis.

Outcome variable	Maintenance treatment group	p
No Relapse vs. Relapse	MPS vs. Others	0.7246
Alive and not on dialysis vs. ESRD or Death	MPS vs. Others	0.0777
CR or PR vs. Non-responders	MPS vs. Others	0.0258*
No Relapse vs. Relapse	MPS vs. MMF	0.2718
Alive and not on dialysis vs. ESRD or Death	MPS vs. MMF	0.6358
CR or PR vs. Non-responders	MPS vs. MMF	0.4089
No Relapse vs. Relapse	MMF vs. others	1.0
Alive and not on dialysis vs. ESRD or Death	MMF vs. others	0.2759
CR or PR vs. Non-responders	MMF vs. others	0.285

CR; complete remission, PR: partial remission,

^*indicates statistically significant result.